TIEFENBACHER PHARMACEUTICALS New market launch: LACOSAMIDE

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be affordable and available for all patients around the world – irrespective of their income level or nationality. That´s why Tiefenbacher Pharmaceuticals is happy to share that we have successfully prepared the launch of the generic version of Lacosamide for a market entry on day one after patent expiration in Australia.

Lacosamide is used for the treatment of seizures improving the life of patients suffering from epilepsy. The tablets will be marketed in Australia in the strengths 50mg, 100mg, 150mg, and 200mg by our partner, one of the biggest generic pharmaceutical companies in the world. Our product has already been launched in time in several patent-free European markets. A launch in further countries will follow as soon as the patents of the originator product expire. With this early market entry, TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

We will keep you updated about generic launches and other products in further international markets.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com